Butyrate as a promising therapeutic target in cancer: From pathogenesis to clinic (Review)

Int J Oncol. 2024 Apr;64(4):44. doi: 10.3892/ijo.2024.5632. Epub 2024 Mar 1.ABSTRACTCancer is one of the leading causes of mortality worldwide. The etiology of cancer has not been fully elucidated yet, and further enhancements are necessary to optimize therapeutic efficacy. Butyrate, a short‑chain fatty acid, is generated through gut microbial fermentation of dietary fiber. Studies have unveiled the relevance of butyrate in malignant neoplasms, and a comprehensive understanding of its role in cancer is imperative for realizing its full potential in oncological treatment. Its full antineoplastic effects via the activation of G protein‑coupled receptors and the inhibition of histone deacetylases have been also confirmed. However, the underlying mechanistic details remain unclear. The present study aimed to review the involvement of butyrate in carcinogenesis and its molecular mechanisms, with a particular emphasis on its association with the efficacy of tumor immunotherapy, as well as discussing relevant clinical studies on butyrate as a therapeutic target for neoplastic diseases to provide new insights into cancer treatment.PMID:38426581 | PMC:PMC10919761 | DOI:10.3892/ijo.2024.5632
Source: International Journal of Oncology - Category: Cancer & Oncology Authors: Source Type: research